FindTrial
Sign In

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02082691
Enrollment
Unknown
Registered
2014-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

G-202, Hepatocellular

Brief summary

Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.

Interventions

DRUGG-202

Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.

Sponsors

GenSpera, Inc.
CollaboratorINDUSTRY
Devalingam Mahalingam
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* History of hepatocellular carcinoma * Participation in prior research study where G-202 was administered * Tolerance of G-202 treatment * Demonstration of stable disease

Exclusion criteria

* Disease progression * Occurrence of unacceptable toxicity

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026